Dry powder drug delivery system and methods
A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
1. A dry powder inhaler comprising:
at least one rigid air conduit and a housing configured to accept a cartridge, the cartridge comprising a lid and
a movable container having a dry powder, the container configured to move relative to the cartridge lid from a storage position to a dispensing position to form a flow path between one or more inlet ports and one or more dispensing ports within the inhaler; and
wherein the dry powder inhaler is configured to emit greater than about 75% of a dry powder from the container as powder particles in a single inhalation, and the powder particles emitted have a volumetric median geometric diameter of less than about 5 microns when the single inhalation generates a peak inspiratory pressure of about 2 kPa within two seconds.
2. The dry powder inhaler of claim 1 having a resistance value to airflow ranging from about 0.065 (√kPa)/liter per minute to about 0.200 (√kPa)/liter per minute.
3. The dry powder inhaler of claim 1 , wherein the dry powder is a formulation for pulmonary delivery and comprises an amount from about 1 mg to about 30 mg of the dry powder.
4. The dry powder inhaler of claim 1 , wherein the dry powder comprises a diketopiperazine or a pharmaceutically acceptable salt thereof.
5. The dry powder inhaler of claim 4 , wherein the diketopiperazine is of the formula 3,6-bis(N-X-4-aminobutyl)-2,5-diketopiperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.
6. The method of claim 5 , wherein the diketopiperazine is
7. The dry powder inhaler of claim 1 , wherein the dry powder comprises a drug or an active agent.
8. The dry powder inhaler of claim 7 , wherein the active agent is an endocrine hormone.
9. The dry powder inhaler of claim 1 , wherein the dry powder comprises a peptide, a polypeptide, or fragments thereof, a small organic molecule or a nucleic acid molecule.
10. The dry powder inhaler of claim 9 , wherein said peptide is insulin, glucagon, glucagon-like peptide-1, parathyroid hormone, oxytocin, oxyntomodulin, peptide YY, an exendin, analogs thereof or fragments thereof.
11. The dry powder inhaler of claim 9 , wherein the small organic molecule is a vasodialator, a vasoconstrictor, a neurotransmitter agonist or a neurotransmitter antagonist.
12. The dry powder inhaler of claim 1 , wherein the single inhalation generates an area under the curve (AUC) from a pressure versus time curve within one second of at least about 1.0, 1.1 or 1.2 kPa*sec.
13. The dry powder inhaler of claim 1 , wherein the container is integrated into the housing and filled with a dry powder.
14. The dry powder inhaler of claim 1 , wherein the inhaler does not include a cartridge.
15. The dry powder inhaler of claim 1 , wherein the cartridge is provided separate from the inhaler and is filled with a dry powder.
16. A method of delivering of a dry powder using a high resistance dry powder inhaler comprising:
a) providing a dry powder inhaler with an airflow resistance value ranging from about 0.065 (√kPa)/liter per minute to about 0.200 (√kPa)/liter per minute, the inhaler containing a dose of the dry powder within a movable container configured to move within the inhaler from a storage position to a dispensing position to form a flow path between one or more inlet ports and one or more dispensing ports within the inhaler,
b) applying sufficient force to reach a peak inspiratory pressure of at least 2 kPa within 2 seconds; and
c) generating an area under the curve in the first second (AUC 0-1 sex ) of a inspiratory pressure versus time curve of at least about 1.0, 1.1 or 1.2 kPa*sec;
wherein greater than 75% of the dose of the dry powder is discharged or emitted from the inhaler as powder particles.
17. The method of claim 16 , wherein the dry powder is a formulation for pulmonary delivery and comprises an amount from about 1 mg to about 30 mg of the dry powder.
18. The method of claim 17 , wherein the dry powder comprises a diketopiperazine or a pharmaceutically acceptable salt thereof.
19. The method of claim 18 , wherein the diketopiperazine is of the formula 3,6-bis(N-X-4-aminobutyl)-2,5-diketopiperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.
20. The method of claim 19 , wherein the diketopiperazine is